Miraqules MedSolutions: Engineering Biomaterials to Stop Bleeding and Save Lives

November 16, 2026 | Monday | Features

From a research breakthrough at NIT Rourkela to a medical innovation entering commercial deployment, Miraqules MedSolutions is developing advanced nanostructured biomaterials for emergency bleeding control, wound management and regenerative medicine. Founded in 2018, the deep-tech life sciences startup is working to make rapid, affordable and accessible hemostatic solutions available across hospitals, emergency services and resource-limited settings.

Problem

Uncontrolled bleeding remains a critical challenge in trauma care, emergency medicine and surgical procedures, particularly when conventional compression methods are difficult to apply. Miraqules aims to address this gap with a biomaterial designed to accelerate bleeding control, including in irregular wounds and hard-to-access bleeding sites.

Product

Its flagship innovation, StopBleed®, is a patented nanostructured hemostatic biomaterial designed to control bleeding in as little as 60 seconds. Its porous, fibrous architecture helps absorb fluids and concentrate platelets and coagulation factors at the bleeding site. It is being developed in powder, applicator-based pellet, gauze and patch formats for different clinical applications.

Proof

StopBleed received regulatory approval in India in February 2026 and has been used across 30+ hospitals and select Indian Army units. The company reports more than 2,000 units sold, approximately ₹8 lakh in realised revenue and a sales pipeline exceeding 3,000 units. It has also secured a paid pilot covering 800 units with the Maharashtra Government for emergency medical services.

People

Founded by Sabir Hossain, Miraqules originated from biomaterials research conducted with his professor, Prof. Devendra Verma, who serves as Chief Scientific Advisor. The leadership team also includes Dr. Mubeen Midda, Co-founder and Chief Marketing Officer. The company's scientific and engineering foundation is supported by expertise in biomedical engineering, biotechnology and clinical medicine.

Purse

Miraqules has secured approximately US$1.17 million through private investment and institutional support. This includes a US$400,000 SAFE investment from GoAhead Ventures in 2021. The company is currently raising a seed round to strengthen manufacturing, accelerate commercial expansion and advance its biomaterials platform.

Plan

The company plans to scale StopBleed manufacturing and expand adoption across Indian hospitals, government healthcare systems and emergency medical services. Following its SLINGSHOT 2026 Grand Winner recognition in Singapore, Miraqules is also exploring opportunities in Southeast Asia, the US and Europe. Its longer-term roadmap includes applications in internal haemorrhage management, wound care, tissue engineering and regenerative medicine.

Why it matters

Rapid bleeding control can be critical in trauma and emergency situations, where delays in intervention can have serious consequences. By developing an indigenous biomaterials platform with applications extending beyond hemostasis, Miraqules is working to address an important clinical need while building India's capabilities in advanced medical materials and life sciences innovation.

FAST FACTS

Particulars

Details

Company

Miraqules MedSolutions

Legal Entity

Miraqules MedSolutions Private Limited

Inception

2018

Origin

NIT Rourkela, India

Industry

MedTech, Life Sciences, Advanced Biomaterials

Founder & CEO

Sabir Hossain

Co-founder & CMO

Dr. Mubeen Midda

Chief Scientific Advisor

Prof. Devendra Verma

Flagship Product

StopBleed®

Core Technology

Nanostructured Hemostatic Biomaterials

Regulatory Milestone

Indian regulatory approval, February 2026

Clinical Adoption

30+ hospitals and select Indian Army units

Patents

11 granted patents across seven international markets

Funding

Approximately US$1.17 million, including institutional support

Key Investor

GoAhead Ventures

Recent Recognition

Grand Winner, SLINGSHOT 2026

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

OR

Forgot your password?

OR

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy